What is it about?
In this review article, we provide an overview of nanocomposites targeting Tumor-associated cells, their use as vaccines and therapeutics, genetic manipulation of the TME, and their combination with chemotherapy and immunotherapy. We also list recent clinical trials and discuss the challenges and opportunities for nanocomposites in cancer treatment.
Featured Image
Why is it important?
The advancements in nanocomposite technology by integrating synergistic functions of different molecules in nanocomposites can modulate the TME and enhance immunotherapeutic outcomes. Combining nanocomposites with chemotherapy and immunotherapy has been explored, highlighting their synergistic ability to improve therapeutic responses. Nanocomposites are also being investigated in clinical trials for immunotherapy, indicating their potential in improving treatment outcomes.
Perspectives
I wrote this article with the thought that there is much nanocomposite research in cancer immunotherapy, but no comprehensive review is available on how many are in the clinical trials. We collected the latest articles and clinical trial information from all the sources and wrote a review article to give a complete picture and future prospection of nanomedicine in cancer immunotherapy. I hope the report will be beneficial and improve future research in this field.
Dr. Prashant Sharma
Read the Original
This page is a summary of: Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy, Bioactive Materials, January 2024, Elsevier,
DOI: 10.1016/j.bioactmat.2023.08.022.
You can read the full text:
Contributors
The following have contributed to this page
